drugset / Trial / NCT07816367
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.
Timeline
- Start
- 2026-10-02
- Primary completion
- 2027-10
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elismetrep | Small molecule | 10 mg | Oral |
| Subject | Elismetrep | Small molecule | 20 mg | Oral |